Certolizumab: clinical trials recruiting now

FDA drug label

FDA-approved

Yes. Certolizumab appears in the FDA drug-label database. Marketed as Cimzia.

Drug class

Tumor Necrosis Factor Blocker (FDA established pharmacologic class)

Mechanism of action

Tumor Necrosis Factor Receptor Blocking Activity (as stated on the FDA label)

Boxed warning

The FDA label for Certolizumab carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely acti…

FDA label via openFDA